Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ARIAD Pharmaceuticals ARIA

Healthcare Biotechnology
"ARIAD Pharmaceuticals Inc is an oncology company. The Company is engaged in transforming the lives of cancer patients with breakthrough medicines. It commercializes & develops products and product candidates including Iclusig, Brigatinib, and AP32788."

Recent & Breaking News (NDAQ:ARIA)

ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer

Business Wire December 5, 2016

ARIAD to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer

Business Wire December 2, 2016

ARIAD Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial

Business Wire November 29, 2016

Biotech Stocks Under Review -- Novavax, Gilead Sciences, Ariad Pharma, and Exelixis

PR Newswire November 21, 2016

ARIAD Announces Data Presentations at the World Conference on Lung Cancer

Business Wire November 16, 2016

ARIAD Announces Launch of Inaugural ALK+ Day During Lung Cancer Awareness Month

Business Wire November 14, 2016

Mid-Afternoon Market Update: Dow Climbs 250 Points; Impax Labs Shares Down Following Q3 Results

Benzinga.com  November 9, 2016

Mid-Day Market Update: Dow Surges Over 100 Points; Coty Shares Slide

Benzinga.com  November 9, 2016

25 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  November 9, 2016

ARIAD Announces Phase 1/2 Trial Data on Investigational Drug Brigatinib Published in The Lancet Oncology

Business Wire November 9, 2016

ARIAD Reports Third Quarter 2016 Financial Results

Business Wire November 7, 2016

ARIAD to Present at the Jefferies 2016 London Healthcare Conference

Business Wire November 2, 2016

ARIAD to Webcast Conference Call on Third Quarter 2016 Financial Results

Business Wire November 1, 2016

ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Brigatinib

Business Wire October 31, 2016

SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Ariad Pharmaceuticals Inc. and Advises Investors with Losses to Contact the Firm

Business Wire October 28, 2016

Glancy Prongay & Murray LLP Commences Investigation on Behalf of Ariad Pharmaceuticals Inc. Investors

Business Wire October 28, 2016

ARIAD Announces Publication of the Preclinical Profile of Brigatinib in the Journal Clinical Cancer Research

Business Wire October 26, 2016

Mid-Afternoon Market Update: ACCO Brands Gains On Earnings Beat; Boise Cascade Shares Down

Benzinga.com  October 24, 2016

Watch These 4 Huge Put Purchases In Friday Trade

Benzinga.com  October 21, 2016

ARIAD Reaffirms Commitment to Discovering and Developing Treatments for Patients with Rare Cancers

Business Wire October 20, 2016